ASCO 2014: Lilly's necitumumab fails to impress with SQUIRE
This article was originally published in Scrip
Eli Lilly is to file its recombinant human IgG1 monoclonal antibody against epidermal growth factor receptor 1 (EGFR 1) necitumumab by the end of the year, based on the Phase III SQUIRE study newly presented at ASCO. However, detailed analysis of the results from the largest study to date in the first-line treatment of stage IV squamous non-small cell lung cancer has left analysts unimpressed by its marginal benefits.
You may also be interested in...
Novartis’s AveXis unit has received a CHMP nod for the spinal muscular atrophy gene therapy at its latest meeting, sending it on the final steps to market in the EU.
The arrival of SARS-CoV-2 has focused attention on a potential new way of making vaccines – one that promises to be quicker and cheaper than traditional methods and more reactive to novel virus outbreaks, but also one that remains to be validated.
The German biotech firm has denied receiving any offer from the Trump administration in a wide-ranging conference call that also addressed recent changes at the top, its clinical timeline for a coronavirus vaccine and new funds from the European Commission to boost production.